ArticleNature2017
Integrated genomic and molecular characterization of cervical cancer.
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04947605 (Epidemiological Landscape of Cervical Cancer in Latin America .), which is not on this map. Cited by 889 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidemiological Landscape of Cervical Cancer in Latin America .
Who cites it
889 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,540 citations in OpenAlex.
- Building bridges to immunotherapy: a knowledge-mapping analysis of cervical cancer organoid research.Frontiers in immunology · 2026Pooled it
- ISUOG/ESGO Consensus Statement on ultrasound-guided biopsy in gynecological oncology.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025Guideline
- SEOM-GEICO Clinical Guidelines on cervical cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study.Signal transduction and targeted therapy · 2025Trial
- Antigen-Presentation Competence in Gynecologic Cancers: Mechanisms, Evidence and Translational Priorities.Cells · 2026Review
- Prognostic Impact of ERAP1 Genetic Variants and Haplotypes in Cervical Cancer: Insights From TCGA-CESC and a Brazilian Patient Cohort.Molecular genetics & genomic medicine · 2026Article
- Workforce and institutional factors associated with comprehensive genomic profiling utilization in gynecologic oncology: a nationwide questionnaire survey in Japan.International journal of clinical oncology · 2026Article
- Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients.PLoS biology · 2026Article
- KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer.Annals of surgery · 2026Article
- Advances in Treatment of Refractory Advanced and Recurrent Cervical Adenocarcinoma: Molecular Heterogeneity and Differences from Squamous Cell Carcinoma.International journal of molecular sciences · 2026Review
- CLEAR-HPV: Interpretable concept discovery for human-papillomavirus-associated morphology in whole-slide histology.Patterns (New York, N.Y.) · 2026Article
- Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma.Cancer medicine · 2026Article
- Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer.Journal of gynecologic oncology · 2026Article
- HPV integration as a triage tool for HPV-positive women in cervical cancer screening.Tumour virus research · 2026Article
- Survival-Associated Molecular and Epigenetic Alterations in Endocervical Adenocarcinoma: An Exploratory TCGA Multi-Omics Cohort Study.Current issues in molecular biology · 2026Article
- Semi-supervised Omics Factor Analysis (SOFA) disentangles known and latent sources of variation in multi-omic data.Nature communications · 2026Article
- The cervicovaginal microbiome: an emerging determinant of HPV infection and disease.Journal of virology · 2026Review
- MicroRNA Dysregulation in HPV-Driven Cervical Cancer: A Review of Oncoprotein-Targeted Signaling Pathways.Life (Basel, Switzerland) · 2026Review
- Basic Clinical Bidirectional Empowerment: Synergistic Breakthrough in Molecular Mechanisms and Clinical Management of Small Cell Cervical Carcinoma.International journal of molecular sciences · 2026Review
829 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
57 authors at 20 institutions in 6 countries.
Funding
Abstract
Cervical cancer remains one of the leading causes of cancer-related deaths worldwide. Here we report the extensive molecular characterization of 228 primary cervical cancers, one of the largest comprehensive genomic studies of cervical cancer to date. We observed notable APOBEC mutagenesis patterns and identified SHKBP1, ERBB3, CASP8, HLA-A and TGFBR2 as novel significantly mutated genes in cervical cancer. We also discovered amplifications in immune targets CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2), and the BCAR4 long non-coding RNA, which has been associated with response to lapatinib. Integration of human papilloma virus (HPV) was observed in all HPV18-related samples and 76% of HPV16-related samples, and was associated with structural aberrations and increased target-gene expression. We identified a unique set of endometrial-like cervical cancers, comprised predominantly of HPV-negative tumours with relatively high frequencies of KRAS, ARID1A and PTEN mutations. Integrative clustering of 178 samples identified keratin-low squamous, keratin-high squamous and adenocarcinoma-rich subgroups. These molecular analyses reveal new potential therapeutic targets for cervical cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.